SEC Form 4 · accession 0001209191-19-012247
TCR2 THERAPEUTICS INC. · TCRR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Feb 19, 2019
Accepted (ET)
Feb 21, 2019 · 6:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001750019
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Feb 19, 2019 | C | 2,421,775 | — | A | 2,421,775 | D | |
| Common StockF1,F2,F3 | Feb 19, 2019 | C | 282,540 | — | A | 2,704,315 | D | |
| Common StockF2,F3 | Feb 19, 2019 | P | 666,667 | $15.00 | A | 3,370,982 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred StockF1 | — | Feb 19, 2019 | C | 15,000,000 | D | — | — | Common Stock | 2,421,775 | 0 | D |
| Series B Preferred StockF1 | — | Feb 19, 2019 | C | 1,750,000 | D | — | — | Common Stock | 282,540 | 0 | D |
Explanation of responses
- F1All shares of Series A Preferred Stock and Series B Preferred Stock automatically converted into the number of shares of the Issuer's common stock on a 6.1938:1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering and had no expiration date.
- F2The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing director of Oncology GP LLC.
- F3The Reporting Persons disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.